Inflammatory bowel diseases

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

Inflammatory bowel diseases

Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, Atreja A, Ron Y, Swaminath A, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen MN, van der Woude CJ, Katsanos KH, Yun L, Tsianos EV, Nathan T, Abreu M, Dotan I, Lashner B, Brynskov J, Terdiman JP, Higgins PD, Chaparro M, Ben-Horin S

Role of the microbiota in inflammatory bowel diseases.

Inflammatory bowel diseases

Nagalingam NA, Lynch SV

Viral hepatitis and inflammatory bowel disease.

Inflammatory bowel diseases

Hou JK, Velayos F, Terrault N, Mahadevan U

Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.

Inflammatory bowel diseases

Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ

Cervical neoplasia risk in IBD: truth or hysteria?

Inflammatory bowel diseases

Mahadevan U

General health maintenance in IBD.

Inflammatory bowel diseases

Moscandrew M, Mahadevan U, Kane S

Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.

Inflammatory bowel diseases

Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ

Management of the pregnant IBD patient.

Inflammatory bowel diseases

Dubinsky M, Abraham B, Mahadevan U

Pages